

LISTING OF CLAIMS:

1. (Previously Presented) A pharmaceutical composition in the form of granules, wherein each granule comprises a neutral microgranule on which is disposed a composition comprising: micronized fenofibrate, a surfactant, and a binding cellulose derivative as a solubilization adjuvant, and

wherein said fenofibrate is present in an amount greater than or equal to 60% by weight, relative to the weight of said pharmaceutical composition, and further wherein said binding cellulose derivative represents between 2 to 15% by weight, relative to the weight of said pharmaceutical composition.

2. (Previously Presented) The pharmaceutical composition of claim 1, wherein said binding cellulose derivative is hydroxypropylmethylcellulose.

3. (Previously Presented) The pharmaceutical composition of claim 2, wherein said hydroxypropylmethylcellulose has an apparent viscosity of between 2.4 and 18 cP.

4. (Previously Presented) The pharmaceutical composition of claim 1, wherein said fenofibrate is present in an amount greater than or equal to 70% by weight, relative to the weight of said pharmaceutical composition.

5. (Previously Presented) The pharmaceutical composition of claim 1, wherein said surfactant is selected from the group consisting of polyoxyethylene 20 sorbitan monooleate, sorbitan monododecanoate, and sodium lauryl sulfate.

6. (Previously Presented) The pharmaceutical composition of claim 1, wherein said surfactant represents between 1 and 10% by weight, relative to the weight of said fenofibrate.
7. (Previously Presented) The pharmaceutical composition of claim 2, wherein said fenofibrate/HPMC mass ratio is between 5/1 and 15/1.
8. (Cancelled)
9. (Previously Presented) The pharmaceutical composition of claim 1, wherein said pharmaceutical composition further comprises at least one excipient.
10. (Previously Presented) The pharmaceutical composition of claim 1, wherein said micronized fenofibrate has a mean particle size less than 15 μm .
11. (Previously Presented) The pharmaceutical composition of claim 1, wherein said composition is contained in gelatin capsules.
12. (Previously Presented) A method for preparing the pharmaceutical composition of claim 1, wherein said granules are prepared by spraying onto neutral microgranules an aqueous suspension of micronized fenofibrate containing surfactant and solubilized binding cellulose derivative.

13. (Cancelled)

14. (Previously Presented) The pharmaceutical composition of claim 3, wherein said hydroxypropylmethylcellulose has an apparent viscosity of between 2.4 and 3.6 cP.

15. (Previously Presented) The pharmaceutical composition of claim 1, wherein said fenofibrate is present in an amount greater than or equal to 75% by weight, relative to the weight of said pharmaceutical composition.

16. (Previously Presented) The pharmaceutical composition of claim 1, wherein said surfactant represents between 3 and 5% by weight, relative to the weight of said fenofibrate.

17. (Previously Presented) The pharmaceutical composition of claim 1, wherein said binding cellulose derivative represents between 5 and 12% by weight, relative to the weight of said pharmaceutical composition.

18. (Previously Presented) The pharmaceutical composition of claim 9, wherein said excipient is selected from the group consisting of a diluent, an antifoaming agent, a lubricant, and a mixture thereof.

19. (Previously Presented) The pharmaceutical composition of claim 9, wherein said excipient is selected from the group consisting of lactose, α -(trimethylsilyl)- ω -

methypoly[oxy-(dimethylsilylene)], a mixture of α -(trimethylsilyl)- ω -methypoly[oxy-(dimethylsilylene)] with silicon dioxide, and talc.

20. (Previously Presented) The pharmaceutical composition of claim 1, wherein said micronized fenofibrate has a mean particle size less than 8 μm .

21. (Previously Presented) A pharmaceutical composition in the form of granules, wherein each granule comprises a neutral microgranule on which is disposed a composition comprising: micronized fenofibrate, a surfactant, and a binding cellulose derivative as a solubilization agent, wherein the mass ratio of said fenofibrate to said binding cellulose derivative is between 5/1 and 15/1.

22. (Previously Presented) The pharmaceutical composition according to claim 21, wherein said binding cellulose derivative is hydroxypropylmethylcellulose.

23. (Previously Presented) The pharmaceutical composition of claim 21, wherein said binding cellulose derivative has an apparent viscosity of between 2.4 and 18 cP.

24. (Previously Presented) The pharmaceutical composition of claim 21, wherein said binding cellulose derivative has an apparent viscosity of between 2.4 and 3.6 cP.

25. (Previously Presented) The pharmaceutical composition of claim 21, wherein said surfactant is selected from the group consisting of polyoxyethylene 20 sorbitan monooleate, sorbitan monododecanoate, and sodium lauryl sulfate.

26. (Previously Presented) The pharmaceutical composition of claim 21, wherein said surfactant represents between 1 and 10% by weight, relative to the weight of said fenofibrate.

27. (Previously Presented) The pharmaceutical composition of claim 21, wherein said surfactant represents between 3 and 5% by weight, relative to the weight of said fenofibrate.

28. (Previously Presented) The pharmaceutical composition of claim 21, wherein said pharmaceutical composition further comprises at least one excipient.

29. (Previously Presented) The pharmaceutical composition of claim 28, wherein said excipient is selected from the group consisting of a diluent, an antifoaming agent, a lubricant, and a mixture thereof.

30. (Previously Presented) The pharmaceutical composition of claim 29, wherein said diluent is lactose.

31. (Previously Presented) The pharmaceutical composition of claim 29, wherein said antifoaming agent is α -(trimethylsilyl)- ω -methylpoly[oxy-(dimethylsilylene)] or a mixture of α -(trimethylsilyl)- ω -methylpoly[oxy-(dimethylsilylene)] with silicon dioxide.

32. (Previously Presented) The pharmaceutical composition of claim 29, wherein said lubricant is talc.

33. (Previously Presented) The pharmaceutical composition of claim 21, wherein said micronized fenofibrate has a mean particle size less than 15 μm .

34. (Previously Presented) The pharmaceutical composition of claim 21, wherein said micronized fenofibrate has a mean particle size less than 8 μm .

35. (Previously Presented) The pharmaceutical composition of claim 21, wherein said composition is contained in gelatin capsules.

36– 46. (Cancelled).

47. (Previously Presented) The pharmaceutical composition of claim 2, wherein at least 95% of said fenofibrate is dissolved at 30 minutes, as measured using a continuous flow cell method with a flow rate of 8 ml/min of sodium lauryl sulfate at 0.1 N.